Intermediate-Risk Newly Diagnosed Metastatic Renal Cell Carcinoma
Intermediate-Risk Newly Diagnosed Metastatic Renal Cell Carcinoma
Case Scenario: A 52-year old male with mRCC
February 2018
- A 52-year old Caucasian man presented to his physician complaining of severe left-sided back pain
- Laboratory findings: mild anemia, otherwise WNL
- CT scan of the abdomen and pelvis showed a large left renal mass, several small lytic lesions in the lumbar and thoracic vertebrae, and a small pulmonary nodule
- The patient underwent cytoreductive nephrectomy
- Diagnosis; stage IV clear-cell renal cell carcinoma; good-risk
- He received radiation therapy to his spinal lesions and was then started on cabozantinib 60 mg daily
- The patient reported moderate nausea and vomiting and diarrhea after 6 weeks on therapy; he continues to do well with improved tolerance after dose adjustment to 40 mg
- Imaging at 3 months showed a significant decrease in size of the pulmonary nodule
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
